Large common fragile site genes and cancer

Seminars in Cancer Biology

Volumn 17, Issue 1, 2007, Pages 31-41

  Smith, David I ^a   McAvoy, Sarah ^a   Zhu, Yu ^a   Perez, Damon S ^a  

^a Mayo Clinic   (United States)

Author keywords

Common fragile site; Large genes

Indexed keywords

PARKIN;

CANCER GENETICS; CARCINOGENESIS; CELL STRESS; CHROMOSOMAL INSTABILITY; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; FHIT GENE; FRA13A GENE; FRA15A GENE; FRA16D GENE; FRA2F GENE; FRA4G GENE; FRA6E GENE; GENE; GENE DELETION; GENE REARRANGEMENT; GRID2 GENE; HUMAN; HUMAN CELL; LRP1B GENE; NEUROBEACHIN GENE; PARKIN GENE; REVIEW; RORA GENE; TUMOR SUPPRESSOR GENE; WWOX GENE;

ACID ANHYDRIDE HYDROLASES; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOME; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; MODELS, GENETIC; NEOPLASM PROTEINS; NEOPLASMS; OXIDOREDUCTASES;

EID: 33846003823     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.10.003     Document Type: Review

References (136)

1. Arlt M.F., Casper A.M., and Glover T.W. Common fragile sites. Cytogenet Genome Res 100 (2003) 92-100
2. Smith D.I., Huang H., and Wang L. Common fragile sites and cancer (review). Int J Oncol 12 (1998) 187-196
3. Glover T.W., Berger C., Coyle J., and Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67 (1984) 136-142
4. Sutherland G.R., and Richards R.I. The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 5 (1995) 323-327
5. Sutherland G.R., and Baker E. The clinical significance of fragile sites on human chromosomes. Clin Genet 58 (2000) 157-161
6. Richards R.I. Dynamic mutations: a decade of unstable expanded repeats in human genetic disease. Hum Mol Genet 10 (2001) 2187-2194
7. Becker N.A., Thorland E.C., Denison S.R., Phillips L.A., and Smith D.I. Evidence that instability within the FRA3B region extends four megabases. Oncogene 21 (2002) 8713-8722
8. Rozier L., El-Achkar E., Apiou F., and Debatisse M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene 23 (2004) 6872-6880
9. Callahan G., Denison S.R., Phillips L.A., Shridhar V., and Smith D.I. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22 (2003) 590-601
10. Sutherland G.R., Parslow M.I., and Baker E. New classes of common fragile sites induced by 5-azacytidine and bromodeoxyuridine. Hum Genet 69 (1985) 233-237
11. Schmid M., Ott G., Haaf T., and Scheres J.M. Evolutionary conservation of fragile sites induced by 5-azacytidine and 5-azadeoxycytidine in man, gorilla, and chimpanzee. Hum Genet 71 (1985) 342-350
12. Smeet D.F., and van de Klundert F.A. Common fragile sites in man and three closely related primate species. Cytogenet Cell Genet 53 (1990) 8-14
13. Rodriquez V., Llambi S., Postiglioni A., Guevara K., Rincon G., Fernandez G., et al. Localization of aphidicolin-induced break points in Holstein-Freisian cattle (Bos Taurus) using RBG banding. Genet Sel Evol 34 (2002) 649-656
14. McAllister B.F., and Greenbaum I.F. How common are common fragile sites: variation of aphicolin-induced chromosomal fragile sites in a population of the deer mouse (Peromyscus manicalatus). Hum Genet 100 (1997) 182-188
15. Smeets D.F., Scheres J.M., and Hustinx T.W. The most common fragile site in man is 3p14. Hum Genet 72 (1986) 215-220
16. Boldog F.L., Gemmill R.M., Wilke C.M., Glover T.W., Nilsson A.S., Chandrasekharappa S.C., et al. Positional cloning of the hereditary renal cell carcinoma 3;8 chromosome translocation breakpoint. Proc Natl Acad Sci USA 90 (1993) 8509-8513
17. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
18. Druck T., Berk L., and Huebner K. FHITness and cancer. Oncol Res 10 (1998) 341-345
19. Huebner K., Garrison P.N., Barnes L.D., and Croce D.M. The role of the FHIT/FRA3B locus in cancer. Ann Rev Genet 32 (1998) 7-31
20. Zimonjic D.N., Druck T., Ohta M., Kastury K., Croce C.M., Popescu N.C., et al. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 57 (1997) 1166-1170
21. Krummel K.A., Roberts L.R., Kawakami M., Glover T.W., and Smith D.I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69 (2000) 37-46
22. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., and Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60 (2000) 2140-2145
23. Reid K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9 (2000) 1651-1663
24. Park S.W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., and Aldaz C.M. Frequent down-regulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91 (2004) 753-759
25. Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Traposso F., Baffa R., et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10 (2004) 3053-3058
26. Ludes-Meyers J.H., Bednarek A.K., Popescu N.C., Bedford M., and Aldaz C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100 (2003) 101-110
27. Huang H., Qian C., Jenkins R.B., and Smith D.I. Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACs spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer 21 (1998) 152-159
28. Mishmar D., Rahat A., Scherer S.W., Nyakatura G., Hinzmann B., Kohwi Y., et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci USA 95 (1998) 8141-8146
29. Arlt M.F., Miller D.E., Beer D.G., and Glover T.W. Molecular characterization of FRAXB and comparative common fragile instability in cancer cells. Genes Chromosomes Cancer 33 (2002) 82-92
30. Denison S.R., Wang F., Becker N.A., Schule B., Kock N., Phillips L.A., et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22 (2003) 8370-8378
31. Kitada T., Asakawa S., Hatori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392 (1998) 605-608
32. Naylor S.L., Johnson B.E., Minna J.D., and Sakaguchi A.Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329 (1987) 451-454
33. Yokoyama S., Yamakawa K., Tsuchiya E., Murata M., Sakiyama S., and Nakamura Y. Deletion mapping on the shor64t arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 52 (1992) 873-877
34. Kovacs G., Erlandsson R., Boldog F., Ingvarsson S., Muller-Bechlin R., Klein G., et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85 (1988) 1571-1575
35. Wang N., and Perkins K.L. Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet 11 (1984) 479-481
36. Rader J.S., Kamarasova T., Huettner P.C., Li L., Li Y., and Gerhard D.S. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene 13 (1996) 2737-2741
37. Maitra A., Wistuba I.I., Gibbons D., Gazdar A.F., and Albores-Saavedra J. Allelic losses at chromosome 3p are seen in human papilloma virus 16 associated transitional carcinoma of the cervix. Gynecol Oncol 74 (1999) 361-368
38. Cohen A.J., Li F.P., Berg S., Marchetto D.J., Tsai S., Jacob S.C., et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301 (1979) 592-595
39. Paradee W., Wilke C.M., Wang L., Shridhar R., Mullins C.M., Hoge A., et al. A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Genomics 35 (1996) 87-93
40. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85 (1996) 17-26
41. Thiagalingam S., Lisitsyn N.A., Hamagauchi M., Wigler M.H., Willson J.K., Markowitz S.D., et al. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 56 (1996) 2936-2939
42. LeBeau M.M., Drabkin H., Glover T.W., Gemmill R., Rassool F.V., Mckeithan T.W., et al. An FHIT tumor suppressor gene?. Genes Chromosomes Cancer 21 (1998) 281-289
43. Wang L., Darling J., Zhang J.S., Qian C.P., Hartmann L., Conover C., et al. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. Oncogene 16 (1998) 635-642
44. Bugert P., Wilhelm M., and Kovacs G. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas. Genes Chromosomes Cancer 20 (1997) 9-15
45. Van den Berg A., Draaijers T.G., Kok K., Timmer T., Van der Veen A.Y., Veldhuis P.M., et al. Normal FHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a line with a homozygous deletion in the FRA3B region. Genes Chromosomes Cancer 19 (1997) 220-227
46. Otterson G.A., Xiao G.H., Geradts J., Jin F., Chen W.D., Niklinska W., et al. Protein expression and functional analyses of the FHIT gene in human tumor cells. J Natl Cancer Inst 90 (1998) 426-432
47. Baffa R., Veronese M.L., Santoro R., Mandes B., Palazzo J.P., Rugge M., et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 58 (1998) 4708-4714
48. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., et al. Loss of FHIT function in lung cancer and preinvasive lesions. Cancer Res 58 (1998) 5032-5037
49. Hadaczek P., Kovatich A., Gronwald J., Lubinski J., Huebner K., and McCue P.A. Loss or reduction of Fhit expression in renal neoplasias: correlation with histogenic class. Hum Pathol 30 (1999) 1276-1283
50. Geradts J., Fong K.M., Zimmerman P.V., and Minna J.D. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathologic features. Br J Cancer 82 (2000) 1191-1197
51. Siprashvili Z., Sozzi G., Barnes L.D., McCue P., Robinson A.K., Eryomin V., et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94 (1997) 13771-13776
52. Ji L., Fang B., Yen N., Fong K., Minna J.D., and Roth J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59 (1999) 3333-3339
53. Dumon K.R., Ishii H., Fong L.Y., Zanesi N., Fidanza V., Mancini R., et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98 (2001) 3346-3351
54. Guerin L.A., Hoffman H.T., Zimmerman M.B., and Robinson R.A. Decreased fragile histidine triad gene expression is associated with worse prognosis in oral squamous carcinoma. Arch Pathol Lab Med 230 (2006) 158-164
55. Arun B., Kilic G., Yen C., Foster B., Yardley D.A., Gaynor R., et al. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14 (2005) 1681-1685
56. Toledo G., Sola J.J., Lozano M.D., Soria E., and Pardo J. Loss of FHIT protein expressin is related to high proliferation, low apoptosis and worse prognosis in non-small cell lung cancer. Mod Pathol 17 (2004) 440-448
57. Wu Y., Meng L., Wang H., Xu Q., Wang S., Wu S., et al. Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. Oncol Rep 16 (2006) 625-629
58. Lee E.J., Lee B.B., Kim J.W., Shim Y.M., Yoseok I., Han J., et al. Aberrant methylation of Fragile Histidine Traid gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 42 (2006) 972-980
59. Gemma A., Hagiwara K., Ke Y., Burke L.M., Khan M.A., Nagashima M., et al. FHIT mutations in human primary gastric cancer. Cancer Res 57 (1997) 1435-1437
60. Ishii H., Dumon K.R., Vecchione A., Fong L.Y., Baffa R., Huebner K., et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 286 (2001) 2441-2449
61. Pichiorri F., Trapasso F., Palumbo T., Aqeilan R.I., Drusco A., Blaser B.W., et al. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 12 (2006) 3494-3501
62. Nakagawa Y., and Akao Y. Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappa B in colon cancer cell lines. Exp Cell Res 312 (2006) 2433-2442
63. Semba S., Trapasso F., Fabbri M., McCorkell K.A., Volinia S., Druck T., et al. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25 (2006) 2860-2872
64. Pekarsky Y., Garrison P.N., Palamarchuk A., Zanesi N., Aqeilan R.I., Huebner K., et al. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101 (2004) 3775-3779
65. Ottey M., Han S.Y., Druck T., Barnoski B.L., McCorkell K.A., Croce C.M., et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91 (2004) 1669-1677
66. Hu B., Han S.Y., Wang X., Ottey M., Potoczek M.B., Dicker A., et al. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202 (2005) 518-523
67. Shiraishi T., Druck T., Mimori K., Flomenberg J., Berk L., Alder H., et al. Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/GHIT and Fra14A2/Fhit. Proc Natl Acad Sci USA 98 (2001) 5722-5727
68. Matsuyama A., Shiraishi T., Trapasso F., Kuroki T., Alder H., Mori M., et al. Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA 100 (2003) 14988-14993
69. Kaplan R., Morse B., Huebner K., Croce C., Howk R., and Ravaera M. Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein tyrosine-phosphatases expressed in brain. Proc Natl Acad Sci 87 (1990) 7000-7004
70. Balsara B.R., Pei J., De Rienzo A., Simon D., Tosolini A., Lu Y.Y., et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30 (2001) 245-253
71. Paris P.L., Witte J.S., Kupelian P.A., Levin H., Klein E.A., Catalona W.J., et al. Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate susceptibility locus. Cancer Res 60 (2000) 3645-3649
72. Hansen L.L., Yilmaz M., Overgaard J., Andersen J., and Kruse T.A. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 58 (1998) 2166-2169
73. Bergsagel P.L., and Luehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
74. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98 (2001) 11417-11422
75. Pimenta F.J., Gomes D.A., Perdigao P.F., Barbosa A.A., Romano-Silva M.A., Gomez M.V., et al. Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer 118 (2006) 174-182
76. Yendamuri S., Kuroki T., Trapasso F., Henry A.C., Dumon K.R., Huebner K., et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63 (2003) 878-881
77. Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10 (2004) 2459-2465
78. Watanabe A., Hippo Y., Tangiguchi H., Iwanari H., Yashiro M., Hirakawa K., et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63 (2003) 8629-8633
79. Van Wezel T., Lombaerts M., van Roon E.H., Philippo K., Baelde H.J., Szuhai K., et al. Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7 (2005) R998-R1004
80. Iliopoulos D., Guler G., Han S.-Y., Druck T., Ottey M., McCokell K.A., et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 232 (2006) 27-36
81. Driouch K., Prydz H., Monese R., Johansen H., Lidereau R., and Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21 (2002) 1832-1840
82. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102 (2005) 15611-15616
83. Chang N.S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276 (2001) 3361-3370
84. O'Keefe L.V., Liu Y., Perkins A., Dayan S., Saint R., and Richards R.I. FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila. Oncogene 24 (2005) 6590-6596
85. Thavathiru E., Ludes-Meyers J.H., MacLeod M.C., and Aldaz C.M. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not IR. Mol Carcinog 44 (2005) 174-182
86. Nunez M.I., Rosen D.G., Ludes-Meyers J.H., Abba M.C., Kil H., Page R., et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 27 (2005) 64
87. Nunez M.I., Ludes-Meyers J., Abba M.C., Kil H., Abbey N.W., Page R.E., et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89 (2005) 99-105
88. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauch W.W., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100 (2004) 1605-1614
89. Qin H.R., Iliopoulos D., Semba S., Fabbri M., Druck T., Volinia S., et al. A role for the WWOX gene in prostate cancer. Cancer Res 66 (2006) 6477-6481
90. Krummel K.A., Denison S.R., Calhoun E., Phillips L.A., and Smith D.I. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer 34 (2002) 154-167
91. Shridhar V., Staub J., Huntley B., Cliby W., Jenkins R., Pass H.I., et al. A novel region of deletion on chromosome 6q23.2 spanning less than 500 kb in high grade invasive epithelial ovarian cancer. Oncogene 18 (1999) 3913-3918
92. Bando K., Matsumoto S., Onda M., Akiyama F., Sakamoto G., Yoshimoto M., et al. Frequent allelic loss at 6q26-q27 in breast carcinomas of the solid-tubular histologic type. Breast Cancer 5 (1998) 127-130
93. Thrash-Bingham C.A., Greenberg R.E., Howard S., Bruzel A., Bremer M., Goll A., et al. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci USA 92 (1995) 2854-2858
94. Luk C., Tsao M.S., Bayani J., Shepherd F., and Squire J.A. Molecular cytogenetic analysis of non-small a cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 125 (2001) 87-99
95. Cesari R., Martin E.S., Calin G.A., Pentimalli F., Bichi R., McAdams H., et al. Parkin, a gene implicated in autosomal recessive juvenile Parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100 (2003) 5956-5961
96. Kuroda Y., Mitsui T., Kunishige M., and Matsumoto T. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun 348 (2006) 787-793
97. Lorenzetti D., Antalffy B., Vogel H., Noveroske J., Armstrong D., and Justice M. The neurological mutant quaking(viable) is Parkin deficient. Mamm Genome 15 (2004) 210-217
98. Barlow D.P., Stoger R., Herrmann B.G., Saito K., and Schweifer N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 349 (1991) 84-87
99. Lau M.M., Stewart C.E., Liu Z., Bhatt H., Rotwein P., and Stewart C.L. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 8 (1994) 2953-2963
100. Oates A.J., Schumaker L.M., Jenkins S.B., Pearce A.A., DaCost S.A., Arun B., et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 47 (1998) 269-281
101. Kong F.M., Anscher M.S., Washington M.K., Killian J.K., and Jirtle R.L. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19 (2000) 1572-1578
102. Wang F., Denison S., Lai J.P., Phillips L.A., Montoya D., Kock N., et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40 (2004) 85-96
103. Lockhart P.J., O'Farrell C.A., and Farrer M.J. It's a double knock-out! The quaking mouse is a spontaneous deletion of Parkin and Parkin co-regulated gene (PACRG). Mov Disord 19 (2004) 101-104
104. Lalouette A., Guenet J.L., and Vriz S. Hotfoot mouse mutations affect the delta 2 glutamate receptor gene and are allelic to lurcher. Genomics 50 (1998) 9-13
105. Guastavino J.M., Sotelo C., and Damez-Kinselle I. Hot-foot murine mutation: behavioral effects and neuroanatomical alterations. Brain Res 523 (1990) 199-210
106. Lalonde R, Strazielle C. Spontaneous and induced mouse mutations with cerebellar dysfunctions: behavior and neurochemistry. Brain Res 2006 [Epub ahead of print].
107. Bluteau O., Beaudoin J.C., Pasturaud P., Belghiti J., Franco D., Bioulac-Sage P., et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 21 (2002) 1225-1232
108. Jetten A.M. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr Drug Targets Inflamm Allergy 32 (2004) 4194-4204
109. Jetten A.M., and Ueda E. Retinoid-related orphan receptors (RORs): roles in cell survival, differentiation and disease. Cell Death Differ 9 (2002) 1167-1171
110. Boukhtouche F., Mariani J., and Tedqui A. The "cholesteROR" protective pathway in the vascular system. Arterioscler Thromb Vasc Biol 24 (2004) 637-643
111. Sato T.K., Panda S., Miraglia L.J., Reyes T.M., Rudic R.D., McNamara P., et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron 43 (2004) 527-537
112. Chauvet C., Bois-Joyeux B., Berra E., Pouyssequr J., and Danan J.L. The gene encoding human retinoic acid-receptor related orphan receptor alpha is a target for hypoxia-inducible factor 1. Biochem J 384 (2004) 79-85
113. Dussault I., Fawcett D., Matthyssen A., Bader J.A., and Giguere V. Orphan nuclear receptor ROR alpha-deficient mice display the cerebellar defects of staggerer. Mech Dev 70 (1998) 147-153
114. Zhu Y., McAvoy S., Kuhn R., and Smith D.I. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25 (2006) 2901-2908
115. Boukhtouche F., Vodjdani G., Jarvis C.I., Bakouche J., Staels B., Mallet J., et al. Human retinoic acid receptor-related orphan receptor alpha1 overexperssion protects neurons against oxidative stress-induced apoptosis. J Neurochem 96 (2006) 1778-1789
116. Rassool F.V., McKeithan T.W., Neilly M.E., van Melle E., Espinosa III R., and LeBEau M.M. Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites. Proc Natl Acad Sci USA 88 (1991) 6657-6661
117. Savelyeva L., Sagulenko E., Schmitt J.G., and Schwab M. Low-frequency common fragile sites: link to neuropsychiatric disorders?. Cancer Lett 232 (2006) 58-69
118. Su Y., Balice-Gordon R.J., Hess D.M., Landsman D.S., Minarcik J., Golden J., et al. Neurobeachin is essential for neuromuscular synaptic transmission. J Neurosci 24 (2004) 3627-3636
119. Denison S.R., Becker N.A., Ferber M.J., Phillips L.A., Kalli K.R., Lee J., et al. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer. Genes Chromosomes Cancer 34 (2002) 406-415
120. Thorland E.C., Myers S.L., Persing D.H., Sarkar G., McGovern R.M., Gostout B.S., et al. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res 60 (2000) 5916-5920
121. Thorland E.C., Myers S.L., Gostout B.S., and Smith D.I. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22 (2003) 1225-1237
122. Ferber M.J., Thorland E.C., Brink A.A., Rapp A.K., Phillips L.A., McGovern R., et al. Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene 22 (2003) 7233-7242
123. Junker K., Weirich G., Moravek P., Podhola M., Ilse B., Hartmann A., et al. Familial and sporadic renal oncocytomas-a comparative molecular genetic analysis. Eur Urol 40 (2001) 330-336
124. Hurst C.D., Fiegler H., Carr P., Williams S., Cartner N.P., and Knowles M.A. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 23 (2004) 2250-2263
125. Liu C.X., Musco S., Lisitsina N.M., Yaklichkin S.Y., and Lisitsyn N.A. Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 69 (2000) 271-274
126. Langbein S., Szakacs O., Wilhelm M., Sukosd F., Weber S., Jauch A., et al. Alteration of the LRP1B gene region is associated with high grade of urothelial cancer. Lab Invest 82 (2002) 639-643
127. Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K., et al. Frequent silencing of the low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 64 (2004) 3741-3747
128. Tanaga K., Bujo H., Zhu Y., Kanaki T., Hirayama S., Takahashi K., et al. LRP1B attenuates the migration of smooth muscle cells by reducing membrane localization of urokinase and PDGF receptors. Arteriscler Thromb Vasc Biol 24 (2004) 1422-1428
129. Cam J.A., Zerbinatti C.V., Knisely J.M., Hecimovic S., Li Y., and Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 279 (2004) 29639-29646
130. Engelman J.A., Zhang X.L., and Lisanti M.P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436 (1998) 403-410
131. Limongi Z.M., Pelliccia F., and Rocchi A. Characterization of the human common fragile site FRA2G. Genomics 81 (2003) 93-97
132. Ciullo M., Debily M.A., Rozier L., Autiero M., Billault A., Mayau V., et al. Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum Mol Genet 11 (2002) 2887-2894
133. Jin H., Gardner R.J., Viswesvaraiah R., Muntoni F., and Roberts R.G. Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21. 3 mental retardation. Eur J Hum Genet 8 (2000) 87-94
134. Song H.H., and Filmus J. The role of glypicans in mammalian development. Biochem Biophys Acta 1573 (2002) 241-246
135. Doughty M.L., De Jager P.L., Korsmeyer S.J., and Heintz N. Neurodegeneration in Lurcher mice occurs via multiple cell death pathways. J Neurosci 20 (2000) 3687-3694
136. Ware M.L., Fox J.W., Gonzalez J.L., Davis N.M., Lambert de Rouvroit C., and Russo C.J. aberrant splicing of a mouse disabled homolog, mdab1, in the scrambler mouse. Neuron 19 (1997) 239-249